Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouthwash antiseptics for reducing salivary SARS-CoV-2 viral load in COVID-19
RBR-10hj7jynPhase 4Recruiting
- Sponsor
- Universidade Estadual do Rio de Janeiro
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of chlorhexidine and hydrogen peroxide in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Universidade Estadual do Rio de Janeiro. Primary endpoints: Salivary SARS-CoV-2 viral load change from baseline immediately after mouthwash use, Salivary SARS-CoV-2 viral load change from baseline at 15 minutes after mouthwash use and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
chlorhexidinehydrogen peroxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-10hj7jyn.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-10hj7jyn.